To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Press Releases
English
Initiator Pharma: Board and management exercises warrants of series TO 2
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) exercise period for warrants of series TO 2 (“TO 2”) is currently ongoing and it ends on Tuesday, December 15, 2020. The Company can today announce that members of the Board and management has exercised TO 2 for a total amount corresponding to approximately SEK 0.5 million. Among those who have exercised their TO 2 are, among others, the Company’s CEO Claus Olesen and chairman Magnus Persson.
Initiator Pharma strengthens its management team and initiates its Scientific Clinical Advisory Board
Initiator Pharma A/S, a clinical-stage biotech company, today announced the appointment of Dr. Allan Wehnert as SVP, Head of Clinical and R&D Strategy and Portfolio Management, and the formation of a Scientific and Clinical Advisory Board (SCAB). The strengthening of the clinical expertise is a direct result of Initiator Pharma’s progress in clinical development of the lead assets IPED2015 and IP2018.
Erik Penser Bank publishes analysis of Initiator Pharma
Initiator Pharma A/S, a clinical-stage biotech company, announced that Erik Penser Bank has made an analysis of the company. Erik Penser Bank’s valuation indicates a justified value of SEK 11-12 (WACC 16%). The valuation rests on the company’s two clinical projects, with IPED2015 and IP2018. For the full analysis, please follow this link ( https://epaccess.penser.se/analys/pa-uppgang/ ).